| 1. Tripathi KD. Essentials of Medical Pharmacology 7th edn. New Delhi: Jaypee Brothers, 2013. p. 82. |
| |
| 2. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009; 4(2):e4439. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
| |
| 3. Wester K, Jonnson AK, Sigset O, Druid H, Hagg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol. 2008;65:573-9. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
| |
| 4. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15-19. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
| |
| 5. Pharmacovigilance Programme of India (PvPI). PvPI: About PvPI. Available at: http://www.ipc.gov.in/PvPI/pv_about.html (last accessed on January 9, 2015). |
| |
| 6. World Health Organization. WHO: Pharmacovigilance. Available at: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/ pharmvigi/en/ (last accessed on January 9, 2015). |
| |
| 7. Pharmacovigilance Programme of India (PvPI). PvPI: ADR Reporting: List of New ADR Monitoring Centres. Available at: http://www. ipc.gov.in/PvPI/60-AMC%20new%20.pdf (last accessed on January 9, 2015). |
| |
| 8. Jha N, Bajracharya O, Shrestha R, Thapa HS, Shankar PR. Starting a pharmacovigilance program within a teaching hospital: challenges and experiences from Lalitpur, Nepal. South Med Rev. 2009;2(1): 7-10. [Pubmed] [PMC Free Fulltext] |
| |
| 9. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32:19-31. [DOI via Crossref] [Pubmed] |
| |
| 10. Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol. 2009;9:14. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
| |
| 11. Bhatia A, Kapoor U, Tayal G. A survey of issues regarding ADR and ADR reporting amongst doctors in Delhi. Int J Risk Saf Med. 2005;17:30-46. |
| |
| 12. Gupta SK, Nayak RP, Shivaranjani R, Vidyarthi SK. A questionnaire study on the knowledge, attitude, and the practice of pharmacovigilance among the healthcare professionals in a teaching hospital in south India. Perspect Clin Res. 2015;6(1):45-52. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
| |
| 13. Rehan HS, Vasudev K, Tripathi CD. Adverse drug reaction monitoring: knowledge, attitude and practices of medical students and prescribers. Natl Med J India. 2002;15:24-6. [Pubmed] |
| |
| 14. Jha N, Ratthore DS, Shankar PR, Gyawali S. Pharmacovigilance knowledge among patients at a teaching hospital in Lalitpur district, Nepal. J Clin Diagn Res. 2014;8(3):32-4. [DOI via Crossref] |
| |
| 15. Elkalmi R, Hassali MA, Al-Lela OQ, Jawad Awadh AI, Al-Shami AK, Jamshed SQ. Adverse drug reactions reporting: knowledge and opinion of general public in Penang, Malaysia. J Pharm Bioallied Sci. 2013;5(3):224-8. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
| |
| 16. Hughes L, Whittlesea C, Luscombe D. Patients’ knowledge and perceptions of the side-effects of OTC medication. J Clin Pharm Ther. 2002;27:243-8. [DOI via Crossref] [Pubmed] |
| |
| 17. Ahmed AM, Izham IM, Subish P. Importance of consumer pharmacovigilance system in developing countries: a case of Malaysia. J Clin Diagn Res. 2010;4(4):2929-35. |
| |
| 18. Palaian S, Alshakka M, Izham M. Developing a consumer reporting program in Malaysia: a novel initiative to improve pharmacovigilance. Pharm World Sci. 2010;32(1):2-6. [DOI via Crossref] [Pubmed] |
| |
| 19. Indian Pharmacopoeia Commission (IPC). Medicines Side Effect Reporting Form (For Consumers). Available at: http://ipc.nic. in/writereaddata/linkimages/Part%202%20of%20Appendix% 2017%20ADR%20Reporting%20Form%20for%20Consumers% 20-1460554002.pdf (last accessed on February 12, 2015). |
| |
| 20. Blenkinsopp A, Wilkie P, Wang M, Routledge PA. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2006;63(2):148-56. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
| |
| 21. Fleuranceau-Morel P. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers. Pharmacoepidemiol Drug Saf. 2002;11:37-44. [DOI via Crossref] [Pubmed] |
| |
| 22. Potharaju HR. Reporting of adverse drug reactions by consumers: rationale and potential. Pharmbit. 2010;22(2):14-21. |
| |
| 23. US Food and Drug Administration. Direct Reporting by Consumers—First International Conference. WHO Pharmaceutical Newsletters [online]. Available at: www.fda.gov/medwatch/safety/ ar95.pdf. |
| |
| 24. Avery AJ, Anderson C, Bond CM, Fortnum H, Gifford A, Hannaford PC, et al. Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1-234. [DOI via Crossref] [Pubmed] |
| |
